JP2025118629A5 - - Google Patents

Info

Publication number
JP2025118629A5
JP2025118629A5 JP2025064114A JP2025064114A JP2025118629A5 JP 2025118629 A5 JP2025118629 A5 JP 2025118629A5 JP 2025064114 A JP2025064114 A JP 2025064114A JP 2025064114 A JP2025064114 A JP 2025064114A JP 2025118629 A5 JP2025118629 A5 JP 2025118629A5
Authority
JP
Japan
Prior art keywords
drawings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025064114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025118629A (ja
Filing date
Publication date
Priority claimed from JP2022516107A external-priority patent/JP7665600B2/ja
Application filed filed Critical
Publication of JP2025118629A publication Critical patent/JP2025118629A/ja
Publication of JP2025118629A5 publication Critical patent/JP2025118629A5/ja
Pending legal-status Critical Current

Links

JP2025064114A 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 Pending JP2025118629A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962900303P 2019-09-13 2019-09-13
US62/900,303 2019-09-13
JP2022516107A JP7665600B2 (ja) 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
PCT/CA2020/051230 WO2021046653A1 (en) 2019-09-13 2020-09-11 Anti-oncolytic virus antigen antibodies and methods of using same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022516107A Division JP7665600B2 (ja) 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2025118629A JP2025118629A (ja) 2025-08-13
JP2025118629A5 true JP2025118629A5 (cg-RX-API-DMAC7.html) 2026-01-21

Family

ID=74867304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516107A Active JP7665600B2 (ja) 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
JP2025064114A Pending JP2025118629A (ja) 2019-09-13 2025-04-09 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022516107A Active JP7665600B2 (ja) 2019-09-13 2020-09-11 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法

Country Status (10)

Country Link
US (1) US20230027475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028417A4 (cg-RX-API-DMAC7.html)
JP (2) JP7665600B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220093103A (cg-RX-API-DMAC7.html)
CN (2) CN118834291A (cg-RX-API-DMAC7.html)
AU (1) AU2020346632A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022004575A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154214A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022002855A (cg-RX-API-DMAC7.html)
WO (1) WO2021046653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4043482A4 (en) * 2019-10-02 2024-03-13 Bionoxx Inc. TUMOR TARGETING PROTEIN OR ASSOCIATED FRAGMENT, ANTIBODIES BINDING THEREWITH AND ITS USE
US20240309070A1 (en) * 2021-03-17 2024-09-19 adMare Therapeutics Society Anti-vaccinia virus antigen antibodies and related compositions and methods
KR102419397B1 (ko) * 2021-04-02 2022-07-14 주식회사 바이오녹스 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도
KR102739298B1 (ko) * 2021-04-02 2024-12-06 주식회사 바이오녹스 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편
CA3216069A1 (en) * 2021-04-05 2022-10-13 Bionoxx Inc. Viral vector-derived target protein for anticancer therapy and binding molecule or fragment thereof specifically binding thereto
CN117480245A (zh) * 2021-04-05 2024-01-30 拜耳诺克斯有限公司 靶向源自溶瘤病毒的蛋白的嵌合抗原受体、表达其的免疫细胞及两者的用途
KR102759386B1 (ko) * 2022-08-11 2025-01-24 성균관대학교산학협력단 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET
KR102770091B1 (ko) * 2023-04-03 2025-02-24 주식회사 셀랩메드 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도
WO2024210531A1 (ko) * 2023-04-03 2024-10-10 주식회사 셀랩메드 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075914A2 (en) * 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies against orthopoxviruses
JP2010507362A (ja) * 2006-08-23 2010-03-11 ケルセジーン ファーマ リミテッド ライアビリティ カンパニー 天然痘モノクローナル抗体
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
BRPI0822556B1 (pt) * 2008-03-26 2022-03-03 Epitomics, Inc Anticorpo monoclonal anti-vegf e composição farmacêutica
US11155622B2 (en) * 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
EA201891420A1 (ru) * 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
AU2018309735B2 (en) * 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
US20240309070A1 (en) * 2021-03-17 2024-09-19 adMare Therapeutics Society Anti-vaccinia virus antigen antibodies and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2025138632A5 (cg-RX-API-DMAC7.html)
JP2025138641A5 (cg-RX-API-DMAC7.html)
JP2024116190A5 (cg-RX-API-DMAC7.html)
JP2024161376A5 (cg-RX-API-DMAC7.html)
JP2024114921A5 (cg-RX-API-DMAC7.html)
JP2022191211A5 (cg-RX-API-DMAC7.html)
JP2025176106A5 (cg-RX-API-DMAC7.html)
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2022184985A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2023103258A5 (cg-RX-API-DMAC7.html)
JP2024059739A5 (cg-RX-API-DMAC7.html)
JP2023145572A5 (cg-RX-API-DMAC7.html)
JP2025160243A5 (cg-RX-API-DMAC7.html)
JP2026004279A5 (cg-RX-API-DMAC7.html)
JP2022543046A5 (cg-RX-API-DMAC7.html)
JP2025098156A5 (cg-RX-API-DMAC7.html)
JP2023181322A5 (cg-RX-API-DMAC7.html)
JP2024149687A5 (cg-RX-API-DMAC7.html)
JP2025084821A5 (cg-RX-API-DMAC7.html)
JP2024099585A5 (cg-RX-API-DMAC7.html)
JP2024112817A5 (cg-RX-API-DMAC7.html)
JP2025090801A5 (cg-RX-API-DMAC7.html)
JP2025094038A5 (cg-RX-API-DMAC7.html)
JP2024045126A5 (cg-RX-API-DMAC7.html)